Investigational Drug Information for Vadastuximab talirine
✉ Email this page to a colleague
What is the drug development status for Vadastuximab talirine?
Vadastuximab talirine is an investigational drug.
There have been 5 clinical trials for Vadastuximab talirine.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2016.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are Seagen Inc., Seattle Genetics, Inc., and [disabled in preview].
Summary for Vadastuximab talirine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 595 |
| WIPO Patent Applications | 346 |
| Japanese Patent Applications | 341 |
| Clinical Trial Progress | Phase 1 (2016-05-01) |
| Vendors | 2 |
Recent Clinical Trials for Vadastuximab talirine
| Title | Sponsor | Phase |
|---|---|---|
| Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | Seagen Inc. | Phase 3 |
| Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | Seattle Genetics, Inc. | Phase 3 |
| Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS | Seagen Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for Vadastuximab talirine
Top disease conditions for Vadastuximab talirine
Top clinical trial sponsors for Vadastuximab talirine
US Patents for Vadastuximab talirine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
